2025-01-22 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational corporation that manufactures and sells medical devices, pharmaceuticals, and consumer packaged goods.

The provided data shows JNJ's cumulative return is significantly lower than the S&P 500 (VOO) over the analyzed period.  While JNJ's cumulative return is 26.45%, VOO's is 120.36%. This results in a substantial negative divergence (-93.9).  The relative divergence of 4.4% indicates that JNJ's performance is in the lower 4.4 percentile relative to its historical performance compared to the S&P 500.  This suggests underperformance compared to the broader market. The CAGR (Compound Annual Growth Rate) data shows a mixed performance over the years, with some periods of strong growth and others showing negative returns, particularly in recent years.  The MDD (Maximum Drawdown) figures also highlight periods of significant losses. The consistently low Alpha values (near zero) indicate the stock's performance closely tracks the market, with little alpha generation.  Beta is relatively stable around 0 (not exactly 0 based on the data given), indicating low correlation with the market.


**2. Recent Price Movement:**

* **Closing Price:** $148.15
* **5-Day Moving Average:** $146.53
* **20-Day Moving Average:** $144.87
* **60-Day Moving Average:** $150.59

The closing price is above the 5 and 20-day moving averages, suggesting a potential short-term uptrend. However, it's below the 60-day moving average, indicating a potential longer-term downtrend.  The recent price increase (0.76) is notable but needs further analysis to determine its sustainability.


**3. Technical Indicators & Expected Return:**

* **RSI (Relative Strength Index):** 58.33 - This suggests the stock is neither overbought nor oversold, indicating a neutral sentiment.
* **PPO (Percentage Price Oscillator):** 0.54 - A positive value suggests potential upward momentum.
* **Delta_Previous_Relative_Divergence:** -4.0 - Indicates a recent short-term downward trend.
* **Expected Return:** -612.4% - This extremely negative projected return over the long term (2+ years) relative to the S&P 500 is a significant red flag, implying significant underperformance is expected.  The extremely negative percentage needs verification. The provided data should be carefully examined to understand the methodology used to obtain this figure.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue        |
|------------|--------|----------------|
| 2024-10-23 | $1.12  | $22.47 Billion |
| 2024-07-25 | $1.95  | $22.45 Billion |
| 2024-05-01 | $1.35  | $21.38 Billion |
| 2024-02-16 | $1.68  | $21.39 Billion |
| 2023-10-27 | $10.32 | $21.35 Billion |

The EPS shows considerable volatility, with a large spike in Q4 2023.  This warrants further investigation to understand the underlying reasons for this fluctuation. Revenue remains relatively stable, with minor fluctuations across quarters.  The extraordinarily high EPS in Q4 2023 needs further analysis to understand whether it represents a one-time event or a shift in the company's earnings trajectory.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue      | Profit Margin |
|------------|---------------|---------------|
| 2024-09-30 | $22.47 Billion | 69.01%        |
| 2024-06-30 | $22.45 Billion | 69.40%        |
| 2024-03-31 | $21.38 Billion | 69.55%        |
| 2023-12-31 | $21.39 Billion | 68.23%        |
| 2023-09-30 | $21.35 Billion | 69.06%        |

Revenue is relatively consistent. Profit margins are high and relatively stable, indicating strong profitability.

**Capital and Profitability:**

| Quarter    | Equity       | ROE           |
|------------|---------------|---------------|
| 2024-09-30 | $70.16 Billion | 3.84%         |
| 2024-06-30 | $71.54 Billion | 6.55%         |
| 2024-03-31 | $70.02 Billion | 4.65%         |
| 2023-12-31 | $68.77 Billion | 5.89%         |
| 2023-09-30 | $71.23 Billion | 36.54%        |

Equity shows minor fluctuations. ROE (Return on Equity) is volatile, with an exceptionally high value in Q3 2023, again requiring further investigation to determine if this is an anomaly.

**7. Overall Analysis:**

JNJ's performance relative to the S&P 500 is concerning, showing significant underperformance. While the company maintains high profit margins and stable revenue, the volatile EPS,  ROE figures, and extremely negative projected long-term returns raise significant concerns. The recent price increase needs confirmation.  Further investigation is required to understand the reasons behind the EPS spike in Q4 2023 and the unusually high ROE in Q3 2023.  The extremely negative expected return (-612.4%) requires urgent clarification of its calculation methodology.  A more detailed fundamental analysis, including an examination of the company's competitive landscape, future growth prospects, and risk factors, is crucial before making any investment decisions.  The current data suggests caution.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough research and consideration of your own risk tolerance.  The accuracy of the data provided is assumed but not guaranteed.
